Declaration of Interests Register										
Technology Appraisal Committee A					Publication Date: 01/07/2020					
Topic: Atezolizur	nab for untreated, lo	ocally advanced or I	metastatic, triple negative,							
PD-L1 positive breast cancer [TA639]										
Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments			
				Interest arose	Interest declared	Interest ceased				
Dr Jeremy Braybrooke	Committee Member	Direct – non financial	co-investigator on clinical trials in breast cancer.	11/09/2019	11/09/2019	-	Declaration made and participated in the appraisal			
							Agreed by Chair Dr Jane Adam			
Dr Mukesh Bindlish Mukesh	Clinical Expert	Direct financial	received payments for speaking and chairing meetings (Roche, Genomic Health, Pfizer, and Novartis),	1/09/2018	11/09/2019	-	Declaration made and participated in the appraisal			
			training services (Roche), and advisory board meetings (Roche). He has also received sponsorship for attending ASCO 2018 and ESMO 2018, which includes registration fees and the costs of accommodation and travel.				Agreed by Chair Dr Jane Adam			
Dr Andrew Wardley	Clinical expert	Direct Financial	Roche advisory and consulting	11/09/2019	11/09/2019	ongoing	Participated in the appraisal			

							Agreed by Chair Dr Jane Adam
Dr Paul Robinson	Committee Member	N/A	Employer is Merck Sharpe and Dohme (MSD), developing a PD1 inhibitor (pembrolizumab) for the same indication. Although not listed as a comparator, but it is likely that MSD will become a competitor during the appraisal	11/09/2019	11/09/2019	-	Absent from the meeting Chair Dr Jane Adam, agreed with the decision.

Link to Committee A interests register : <u>https://www.nice.org.uk/Media/Default/Get-involved/Meetings-In-Public/Technology-appraisal-</u> committee/TAC-A-interests-register.pdf

GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER

Relevant dates: Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.